Virtual hydrate screening and coformer selection for improved relative humidity stability

被引:26
作者
Abramov, Yuriy A. [1 ]
机构
[1] Pfizer Global Res & Dev, Groton, CT 06340 USA
来源
CRYSTENGCOMM | 2015年 / 17卷 / 28期
关键词
CAMBRIDGE STRUCTURAL DATABASE; CRYSTAL-STRUCTURES; SOLID-STATE; PHARMACEUTICAL COCRYSTALLIZATION; PHYSICOCHEMICAL PROPERTIES; DEHYDRATION KINETICS; MOLECULAR-STRUCTURE; DRUG DISCOVERY; WATER ACTIVITY; CO-CRYSTAL;
D O I
10.1039/c4ce02523g
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
Drug formulations of anhydrous solid forms are generally preferred over hydrated forms. This is due to the risks of low exposure and unacceptable physical and chemical stability in comparison with anhydrous formulations. The purpose of the current study was to determine which descriptors can be most efficiently applied to virtual screening in order to provide answers to the following questions: 1) what is the propensity to form a solid state hydrate of a pharmaceutical compound, and 2) in regards to cocrystalline formulation, which coformer would provide for the highest stability with respect to relative humidity (RH) conditions? A number of properties of different complexity were tested to provide answers to these questions, including COSMO-RS excess free energy G(ex) and enthalpy H-ex of hydration of the compound in amorphous state; octanol-water partition coefficient clogP; polar surface area TPSA; different combinations of molecular H-bond donor and acceptor counts; an excess enthalpy of API (active pharmaceutical ingredient)-coformer mixing; and coformer solubilities. It was demonstrated that the G(ex) property provides the most efficient way of virtual screening of hydration propensity of solid pharmaceutical compounds. It was also demonstrated that a virtual coformer screening based on the API coformer miscibility, as measured by the COSMO-RS H-ex property, may be efficiently used to guide the experimental selection of coformers which have an increased probability of cocrystallization and provide the highest RH stability.
引用
收藏
页码:5216 / 5224
页数:9
相关论文
共 83 条
  • [1] Abramov Y.A., 2010, CHEM ENG PHARM IND R, P477, DOI DOI 10.1002/9780470882221
  • [2] Current Computational Approaches to Support Pharmaceutical Solid Form Selection
    Abramov, Yuriy A.
    [J]. ORGANIC PROCESS RESEARCH & DEVELOPMENT, 2013, 17 (03) : 472 - 485
  • [3] Rational coformer or solvent selection for pharmaceutical cocrystallization or desolvation
    Abramov, Yuriy A.
    Loschen, Christoph
    Klamt, Andreas
    [J]. JOURNAL OF PHARMACEUTICAL SCIENCES, 2012, 101 (10) : 3687 - 3697
  • [4] The Cambridge Structural Database: a quarter of a million crystal structures and rising
    Allen, FH
    [J]. ACTA CRYSTALLOGRAPHICA SECTION B-STRUCTURAL SCIENCE, 2002, 58 (3 PART 1): : 380 - 388
  • [5] Anderson K. M., 2008, ANGEW CHEM, V120, P1074
  • [6] Solid-state studies on the hemihydrate and the anhydrous forms of flunisolide
    Bartolomei, M
    [J]. JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2000, 24 (01) : 81 - 93
  • [7] Pharmaceutical Co-crystals with Isonicotinamide-Vitamin B3, Clofibric Acid, and Diclofenac-and Two Isonicotinamide Hydrates
    Bathori, Nikoletta B.
    Lemmerer, Andreas
    Venter, Gerhard A.
    Bourne, Susan A.
    Caira, Mino R.
    [J]. CRYSTAL GROWTH & DESIGN, 2011, 11 (01) : 75 - 87
  • [8] DENSITY-FUNCTIONAL EXCHANGE-ENERGY APPROXIMATION WITH CORRECT ASYMPTOTIC-BEHAVIOR
    BECKE, AD
    [J]. PHYSICAL REVIEW A, 1988, 38 (06): : 3098 - 3100
  • [9] Bhattacharya A, 2010, ACTA CRYSTALLOGR C, V66, pO329, DOI [10.1107/S010827011002031, 10.1107/S0108270110020317]
  • [10] Over one hundred solvates of sulfathiazole
    Bingham, AL
    Hughes, DS
    Hursthouse, MB
    Lancaster, RW
    Tavener, S
    Threlfall, TL
    [J]. CHEMICAL COMMUNICATIONS, 2001, (07) : 603 - 604